2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of …
E Arbelo, A Protonotarios, JR Gimeno… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the task force for the …
K Zeppenfeld, J Tfelt-Hansen, M De Riva… - European heart …, 2022 - academic.oup.com
4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …
Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study
R Garcia, N Combes, P Defaye, K Narayanan… - EP …, 2021 - academic.oup.com
Aims We aimed to provide contemporary real-world data on wearable cardioverter-
defibrillator (WCD) use, not only in terms of effectiveness and safety but also compliance …
defibrillator (WCD) use, not only in terms of effectiveness and safety but also compliance …
[HTML][HTML] Wearable cardioverter defibrillator for preventing sudden cardiac death in patients at risk: An updated systematic review of comparative effectiveness and …
Objectives To synthesise the available evidence of wearable cardioverter defibrillator (WCD)
therapy as an add-on measure to optimal medical therapy (OMT) or as a replacement of …
therapy as an add-on measure to optimal medical therapy (OMT) or as a replacement of …
Prognostic value of ventricular arrhythmia in early post-infarction left ventricular dysfunction: the French nationwide WICD-MI study
M Echivard, JM Sellal, C Ziliox, E Marijon… - European Heart …, 2024 - academic.oup.com
Abstract Background and Aims Prophylactic implantable cardioverter–defibrillators (ICDs)
are not recommended until left ventricular ejection fraction (LVEF) has been reassessed 40 …
are not recommended until left ventricular ejection fraction (LVEF) has been reassessed 40 …
[HTML][HTML] Critical appraisal of “Goetz G, Wernly B, Wild C (2023) Wearable cardioverter defibrillator for preventing sudden cardiac death in patients at risk: An updated …
M Nürnberg, F Semrau - International Journal of Cardiology. Heart …, 2023 - ncbi.nlm.nih.gov
2 world-wide accepted, useful approach to save lives by defibrillation of deadly VT/VF
events until a permanent ICD therapy is clearly indicated or considered unnecessary …
events until a permanent ICD therapy is clearly indicated or considered unnecessary …
Wearable cardioverter-defibrillators: A review of evidence and indications
CC Cheung, JE Olgin, BK Lee - Trends in cardiovascular medicine, 2021 - Elsevier
The wearable cardioverter-defibrillator (WCD) was first approved for clinical use in 2002,
and is routinely used in select populations at high risk for sudden cardiac death. WCDs are …
and is routinely used in select populations at high risk for sudden cardiac death. WCDs are …
Wearable cardioverter defibrillator multicentre experience in a large cardiac surgery cohort at transient risk of sudden cardiac death
C Kuehn, S Ruemke, P Rellecke… - European Journal of …, 2022 - academic.oup.com
OBJECTIVES The wearable cardioverter defibrillator (WCD) is an established, safe, effective
solution, protecting patients at risk of sudden cardiac death. We specifically investigated …
solution, protecting patients at risk of sudden cardiac death. We specifically investigated …
Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure
K Iliodromitis, Z Balogh, F Triposkiadis… - Frontiers in …, 2023 - frontiersin.org
Background The wearable cardioverter defibrillator (WCD),(LifeVest, ZOLL, Pittsburgh, PA,
USA) is a medical device designed for the temporary detection and treatment of malignant …
USA) is a medical device designed for the temporary detection and treatment of malignant …
[HTML][HTML] Wearable devices, ischemic heart disease and cardiovascular outcomes: A systematic review and meta-analysis
JMA Ballavenuto, N Tongtip, NLS Fischer, M Bardus - Maturitas, 2025 - Elsevier
Objectives To evaluate the impact of wearable devices when associated with usual care on
the incidence of major adverse cardiovascular events (MACE) in patients with ischemic …
the incidence of major adverse cardiovascular events (MACE) in patients with ischemic …